The niacin skin flush abnormality in schizophrenia: A quantitative dose-response study

Schizophrenia Research

Volumn 62, Issue 3, 2003, Pages 251-258

  Messamore, Erik ^a,b,c   Hoffman, William F ^a,b,c   Janowsky, Aaron ^b,c,d  

^a Mental Health and Clinical Neurosciences Division   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Laser Doppler flowmetry; Niacin; Prostaglandins; Schizophrenia; Skin flush

Indexed keywords

ALPHA METHYLNICOTINATE; NICOTINIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SENSITIVITY; FEMALE; FLUSHING; HUMAN; LASER DOPPLER FLOWMETRY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCHIZOPHRENIA; SKIN BLOOD FLOW; STATISTICAL SIGNIFICANCE; STUDY; VASODILATATION;

EID: 0038121675     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(02)00311-0     Document Type: Article

References (28)

1. Andersen P.H., Abrams K., Bjerring P., Maibach H. A time-correlation study of ultraviolet B-induced erythema measured by reflectance spectroscopy and laser Doppler flowmetry. Photodermatol. Photoimmunol. Photomed. 8:1991;123-128.
2. Andersson R.G., Aberg G., Brattsand R., Ericsson E., Lundholm L. Studies on the mechanism of flush induced by nicotinic acid. Acta Pharmacol. Toxicol. 41:1977;1-10.
3. Endrenyi L., Patel M. Evaluation of two assumptions: single straight line and single normal distribution. Trends Pharmacol. Sci. 12:1991;293-296.
4. Fiedler P., Wolkin A., Rotrosen J. Niacin-induced flush as a measure of prostaglandin activity in alcoholics and schizophrenics. Biol. Psychiatry. 21:1986;1347-1350.
5. Glen A.I., Glen E.M., Horrobin D.F., Vaddadi K.S., Spellman M., Morse-Fisher N., Ellis K., Skinner F.S. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr. Res. 12:1994;53-61.
6. Glen A.I., Cooper S.J., Rybakowski J., Vaddadi K., Brayshaw N., Horrobin D.F. Membrane fatty acids, niacin flushing and clinical parameters. Prostaglandins Leukot. Essent. Fat. Acids. 55:1996;9-15.
7. Holloway G.A., Watkins D.W. Laser Doppler measurement of cutaneous blood flow. J. Invest. Dermatol. 69:1977;306-309.
8. Hudson C.J., Lin A., Cogan S., Cashman F., Warsh J.J. The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia? Biol. Psychiatry. 41:1997;507-513.
9. Hudson C., Gotowiec A., Seeman M., Warsh J., Ross B.M. Clinical subtyping reveals significant differences in calcium-dependent phospholipase A2 activity in schizophrenia. Biol. Psychiatry. 46:1999;401-405.
10. Maurice P.D.L., Barr R.M., Koro O., Greaves M.W. The effect of prostaglandin D2 on the response of human skin to histamine. J. Invest. Dermatol. 89:1987;245-248.
11. Mills C.M., Hill S.A., Marks R. Transdermal nicotine suppresses cutaneous inflammation. Arch. Dermatol. 133:1997;823-902.
12. Morrow J.D., Parsons W.G., Roberts L.J. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins. 38:1989;263-274.
13. Morrow J.D., Awad J.A., Oates J.A., Roberts L.J. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J. Invest. Dermatol. 98:1992;812-815.
14. Peet M., Laugharne J.D., Horrobin D.F., Reynolds G.P. Arachidonic acid: a common link in the biology of schizophrenia? Arch. Gen. Psychiatry. 51:1994;665-666.
15. Plummer N.A., Hensby C.N., Black A.K., Greaves M.W. Prostaglandin activity in sustained inflammation of human skin before and after aspirin. Clin. Sci. Mol. Med. 52:1977;615-620.
16. Puri B.K., Easton T., Das I., Kidane L., Richardson A.J. The niacin skin flush test in schizophrenia: a replication study. Int. J. Clin. Pract. 55:2001;368-370.
17. Rybakowski J., Weterle R. Niacin test in schizophrenia and affective illness. Biol. Psychiatry. 29:1991;834-836.
18. Sadock, B.J. and Sadock, V.A. (Eds.), 2000. Kaplan and Sadock's Comprehensive Textbook of Psychiatry, 7th edn. Lippincott Williams and Wilkins, Philadelphia, pp. 1402 and 2360.
19. Seifalian A.M., Stansby G., Jackson A., Hamilton G. Comparison of laser Doppler perfusion imaging, laser Doppler flowmetry, and thermographic imaging for assessment of blood flow in human skin. Eur. J. Vasc. Surg. 8:1994;65-69.
20. Shah S.H., Vankar G.K., Peet M., Ramchand C.N. Unmedicated schizophrenic patients have a reduced skin flush in response to topical niacin. Schizophr. Res. 43:2000;163-164.
21. Smesny S., Riemann S., Riehemann S., Bellemann M.E., Sauer H. Quantitative measurement of induced skin reddening using optical reflection spectroscopy - methodology and clinical application. Biomed. Tech. 46:2001;280-286.
22. Turenne S.D., Seeman M., Ross B.M. An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine, and nicotine upon nicotinic acid response. Schizophr. Res. 50:2001;191-197.
23. Waldo M. Co-distribution of sensory gating and impaired niacin flush response in the parents of schizophrenics. Schizophr. Res. 40:1999;49-53.
24. Ward P.E., Sutherland J., Glen E.M., Glen A.I. Niacin skin flush in schizophrenia: a preliminary report. Schizophr. Res. 29:1998;269-274.
25. Wilkin J.K. Chlorpropamide-alcohol flushing, malar thermal circulation index, and baseline malar temperature. Metabolism. 31:1982;948-958.
26. Wilkin J.K., Fortner G., Reinhardt L.A., Flowers O.V., Kilpatrick S.J., Streeter W.C. Prostaglandins and nicotinate-provoked increase in cutaneous blood flow. Clin. Pharmacol. Ther. 38:1985;273-277.
27. Wilson D.W., Douglass A.B. Niacin skin flush is not diagnostic of schizophrenia. Biol. Psychiatry. 21:1986;974-977.
28. Winkelmann R.K., Wilhelmj C.M., Horner F.A. Experimental studies on dermographism. Arch. Dermatol. 92:1965;436-442.